Pediatric Brain Tumor Clinical Trials

Questions about patients' participation in the following clinical trials can be directed to Dennis Aguiling by calling 415.476.3982 or by e-mail at AguilingD@peds.ucsf.edu. Alternatively, to contact the nurse practitioner in charge, please call 415.476.3831.

Newly Diagnosed Tumor

Diffuse Pontine Glioma
Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas (PBTC 021): This is a phase I trial for children with newly diagnosed, diffuse intrinsic brain stem gliomas and high-grade gliomas.
Study Details

High-grade Glioma
A Phase II Study of Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma (Children’s Oncology Group Study ACNS0621).

Low-grade Glioma
A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Gliomas; a Groupwide Phase II Study (Children's Oncology Group Study ACNS0221 ). Study Details.

Medulloblastoma and Primitive Neural Ectodermal Tumor
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial (Children's Oncology Group Study ACNS0331).
Study Details

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients (Children's Oncology Group Study ACNS0332). Study Details

A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate (Children's Oncology Group Study ACNS0334).

A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449 (PBTC-025). This is a phase I trial for children between 3 and 21 years old with recurrent or refractory medulloblastoma. Study Details

A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma (PBTC-025B). Study Details

Atypicial Teratoid/Rhabdoid Tumor
Neoadjuvant Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation(Children's Oncology Group Study ACNS0333).
Study Details

Recurrent Disease

A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis (PBTC 019). This is a phase I trial for children between 3 and 21 years old with cancer that has spread to the lining of the brain and/or spinal cord (neoplastic meningitis). Study Details

Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors (PBTC 020). This is a phase I trial for patients = 21 years of age with recurrent or refractory tumors of the central nervous system. Study Details

Phase II study of bevacizumab plus Irinotecan (Camptosar^TM) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas and Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, and Ependymomas (PBTC 022). This is a phase II trial for children with recurrent malignant glioma and diffuse brainstem glioma. Study Details

Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors (PBTC 023). This is a phase I trial for children who are less than 21 years of age and who have been diagnosed and treated previously for any type of brain tumor. Study Details

A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies (PBTC-024). This is a phase I trial for children leess than 21 years of age who have been diagnosed and treated previously for any type of high-grade malignant glioma or a diffuse brainstem glioma. Study Details

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors (PBTC-027). This is a phase I trial for patients ≤ 21 years of age with recurrent or refractory tumors of the central nervous system. Study Details

A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors (Children’s Oncology Group Study ADVL0612). Study Details

A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (Children’s Oncology Group Study ADVL0912). Study Details

A Phase II Study of Bevacizumab and Lapatinib in Children with Recurrent or Refractory ependymoma (CERN08-01). This is a Phase II study for children less than 21 years of age with recurrent or refractory ependymoma. Study Details

A Phase I Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors (Amgen Study 20050252). Study Details